Financing type:  underwritten prospectus offering

Gross proceeds:  $130-million (U.S.)

Offering:  29,885,057 common listed shares

Offering price:  $4.35 (U.S.) per listed share

Warrant exercise terms:  nil

Overallotment option:  The underwriters may purchase a maximum of 4,482,758 common listed shares for overallotment purposes. As of Nov. 7, 2025, such option remains outstanding and no common listed shares have been issued thereunder. All information presented herein includes such exercise.

Commissions in securities:  nil

Disclosure:  Refer to the prospectus dated Oct. 16, 2025, and the company's news releases dated Oct. 16, 2025, and Oct. 20, 2025.